US 10,300,070 B2Granted

Metabolically-activated drug conjugates to overcome resistance in cancer therapy

AssigneeThe Brigham and Women's Hospital, Inc.

InventorsAaron Goldman, Shiladitya Sengupta, Abhimanyu Paraskar

Life of this patent

Estimating the term…

Described are combination therapies and metabolically-activated drug conjugates and their use in treating cancer in subjects.

Dependent claims

A metabolically-activated drug conjugate having the structure:

Dependencies are inferred from the claim text.

A61K 31/5377
1,4-Oxazines, e.g. morpholine: not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/704
Attached to a carbocyclic compound, e.g. phloridzin: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin,…
A61K 31/7068
Containing condensed or non-condensed pyrimidines: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…

From the US filing history. Foreign family members aren’t listed.

Loading patent…